Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9


Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) ? a rare, life-threatening genetic disease ? and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, and alpha-1 antitrypsin deficiency.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune's Best Workplaces in Biotechnology and Pharmaceuticals and Best Workplaces for Women. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)


These press releases may also interest you

at 21:45
The "Lung Cancer Diagnostics: Global Strategic Business Report" report has been added to  ResearchAndMarkets.com's offering. Global Lung Cancer Diagnostics Market to Reach $4.7 Billion by 2030 The global market for Lung Cancer Diagnostics estimated...

at 21:00
Incyte today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of...

at 19:41
Medtronic plc (the "Company") announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and...

at 19:03
Today, Ontario's Doug Ford government introduced a budget that puts private profits and private interests over people, fair pay, and public services....

at 19:00
Canada House Cannabis Group Inc. (formerly Canada House Wellness Group Inc.) ("Canada House" or the "Company") is pleased to report its financial results for the three months ending January 31, 2023. All amounts are stated in thousands of Canadian...

at 18:55
Vitalhub Corp. (the "Company" or "Vitalhub") announced today it has filed its Consolidated Financial Statements and Management's Discussion and Analysis report for the year ended December 31, 2022, with the Canadian securities authorities. These...



News published on 4 january 2023 at 08:10 and distributed by: